Coated Stent Graft Market Size, Share, Growth, and Industry Analysis, By Type (Hemodialysis Access Graft,Endovascular Stent Graft,Peripheral Vascular,Other), By Application (Cardiovascular Diseases,Cardiac Aneurysm,Kidney Failure,Other), Regional Insights and Forecast to 2035

Coated Stent Graft Market Overview

Global Coated Stent Graft market size is estimated at USD 1497.7 million in 2026 and is expected to reach USD 2549.1 million by 2035 at a 6.1% CAGR.

The Coated Stent Graft Market is driven by the increasing global burden of vascular diseases, with more than 200 million people affected by peripheral artery disease worldwide in 2023. Approximately 20 million new cardiovascular cases are reported annually, and nearly 35% of interventional vascular procedures involve stent graft implantation. Over 60% of endovascular aneurysm repairs utilize coated stent graft technologies to reduce thrombosis and restenosis risks. Polymer-coated devices account for nearly 55% of total product installations, while heparin-bonded grafts represent around 28% of coated applications. The Coated Stent Graft Market Size is strongly influenced by minimally invasive procedures, which represent over 70% of vascular interventions globally.

In the United States, more than 6.5 million adults are diagnosed with peripheral artery disease, and approximately 200,000 abdominal aortic aneurysm (AAA) repairs are performed annually. Nearly 65% of AAA repairs are conducted using endovascular techniques, with coated stent grafts used in over 75% of these procedures. Around 785,000 strokes occur each year in the U.S., contributing to high vascular intervention volumes. Approximately 48% of dialysis patients rely on vascular grafts for hemodialysis access, and over 30% of these utilize coated graft systems. The Coated Stent Graft Market Share in the U.S. is influenced by advanced hospital infrastructure, with more than 6,000 hospitals performing interventional procedures.

Key Findings

• Key Market Driver: Over 72% procedural preference for minimally invasive surgery, 65% endovascular repair adoption, 58% reduction in restenosis with coated grafts, and 60% utilization rate in aneurysm interventions.
• Major Market Restraint: Approximately 34% high device cost impact, 29% reimbursement limitations, 26% post-implantation complications, and 31% regulatory approval delays across multiple regions.
• Emerging Trends: Nearly 48% adoption of heparin-bonded coatings, 42% shift toward bioactive polymer coatings, 36% integration with drug-eluting layers, and 40% rise in hybrid surgical techniques.
• Regional Leadership: North America holds 38% procedure volume share, Europe accounts for 27%, Asia-Pacific represents 24%, and over 65% of advanced coated graft procedures occur in developed economies.
• Competitive Landscape: Top 5 companies control 68% of global unit shipments, while top 2 manufacturers account for nearly 44% market share and 70% of large-diameter graft supply contracts.
• Market Segmentation: Endovascular stent grafts contribute 52% of installations, hemodialysis access grafts account for 23%, peripheral vascular applications hold 18%, and other types represent 7%.
• Recent Development: In 2024, 46% of newly approved grafts featured advanced polymer coatings, 39% incorporated heparin bonding, 33% improved flexibility metrics, and 28% extended durability beyond 10 years.

Coated Stent Graft Market Latest Trends

The Coated Stent Graft Market Trends indicate growing preference for bioactive and heparin-coated grafts, which reduce thrombosis by nearly 40% compared to non-coated alternatives. Approximately 60% of abdominal aortic aneurysm procedures now use coated endovascular stent grafts. Hybrid procedures combining open and endovascular techniques increased by 35% between 2020 and 2024.

Nearly 42% of newly launched coated stent graft products in 2023 incorporated anti-inflammatory polymer layers to reduce intimal hyperplasia. Around 36% integrated drug-eluting properties to decrease restenosis rates below 15% within 12 months post-implantation. The Coated Stent Graft Market Analysis shows that 55% of hospitals prefer grafts with durability exceeding 8 years. Additionally, 50% of interventional cardiologists report improved patient outcomes with coated grafts compared to bare-metal devices.

Miniaturization advancements reduced delivery system diameters by 18% over 5 years, allowing treatment of vessels smaller than 5 mm in 30% of procedures. These technological improvements contribute significantly to Coated Stent Graft Market Growth and long-term device adoption.

Coated Stent Graft Market Dynamics

Dynamics refers to the measurable forces, variables, and interactions that influence change, movement, and development within a system over a defined period. In a business or market context, dynamics describe how quantified factors such as demand levels, supply conditions, adoption rates, regulatory impact, technological advancement percentages, and competitive intensity collectively shape industry performance. For example, if 65% of procedures shift toward minimally invasive techniques, 34% of buyers face cost constraints, 48% of providers adopt new technology, and 22% experience operational challenges, these numerical indicators represent market dynamics. It is the structured evaluation of drivers, restraints, opportunities, and challenges expressed through statistical data, percentages, penetration rates, and volume metrics that determine overall market direction.

DRIVER

"Rising prevalence of cardiovascular and vascular diseases."

Cardiovascular diseases account for nearly 32% of global deaths, equating to approximately 20 million fatalities annually. Peripheral artery disease affects more than 200 million individuals worldwide, and abdominal aortic aneurysms occur in 4% to 8% of men over age 65. Over 65% of aneurysm repairs are now performed using endovascular techniques. Approximately 70% of vascular surgeons prefer minimally invasive procedures due to 25% shorter hospital stays and 30% lower complication rates. The Coated Stent Graft Market Growth is further supported by increasing dialysis cases, with over 3.5 million patients worldwide undergoing hemodialysis and nearly 45% requiring vascular graft access.

RESTRAINT

"High device costs and reimbursement limitations."

Nearly 34% of hospitals cite high procurement costs as a barrier to adopting advanced coated graft systems. Around 29% of emerging markets report partial reimbursement coverage for endovascular procedures. Post-implantation complications occur in 20% to 25% of cases, influencing clinical caution. Regulatory approval timelines average 18 to 36 months in 40% of developed regions. Approximately 31% of healthcare providers report limited budget allocation for high-end coated devices, impacting Coated Stent Graft Market Outlook in cost-sensitive countries.

OPPORTUNITY

" Expansion of minimally invasive and hybrid surgical procedures."

Minimally invasive vascular procedures represent over 70% of total interventions globally. Hybrid operating rooms increased by 28% between 2019 and 2024. Around 48% of vascular surgeons report transitioning to coated grafts for improved patency rates exceeding 85% at 24 months. Asia-Pacific shows 35% annual increase in endovascular procedure volumes. The Coated Stent Graft Market Opportunities expand with aging populations, as individuals aged 60+ account for 55% of aneurysm cases and 60% of dialysis demand.

CHALLENGE

"Device-related complications and durability concerns."

Endoleaks occur in approximately 15% to 20% of endovascular aneurysm repairs. Device migration rates range between 3% and 6% within 5 years post-implantation. Around 22% of patients require secondary interventions within 3 years. Nearly 30% of clinicians emphasize long-term durability beyond 10 years as a primary requirement. Biocompatibility failures affect roughly 5% of implants, influencing Coated Stent Graft Market Analysis regarding safety benchmarks.

Coated Stent Graft Market Segmentation

The Coated Stent Graft Market Size is segmented by type and application, with endovascular stent grafts accounting for 52% of installations, hemodialysis access grafts representing 23%, peripheral vascular grafts holding 18%, and other applications comprising 7%. Cardiovascular diseases dominate with 46% application share, followed by cardiac aneurysm at 28%, kidney failure at 19%, and other uses at 7%.

By Type

Hemodialysis Access Graft: Hemodialysis access grafts are used primarily in patients with end-stage renal disease, with more than 3.5 million individuals worldwide undergoing dialysis treatment. Approximately 45% of dialysis patients require arteriovenous graft placement for vascular access. Coated hemodialysis grafts reduce infection rates by nearly 25% and improve 12-month primary patency rates to around 60% compared to 45% in non-coated grafts. In the U.S., over 500,000 patients receive dialysis annually, and nearly 48% rely on synthetic vascular grafts. Heparin-bonded coatings are utilized in about 30% of newly implanted dialysis grafts, helping lower thrombosis incidence by approximately 35% within the first 6 months post-implantation.

Endovascular Stent Graft: Endovascular stent grafts represent the largest procedural segment, accounting for nearly 52% of coated stent graft utilization. More than 200,000 abdominal aortic aneurysm repairs are performed globally each year, with over 65% conducted through endovascular techniques. Coated stent grafts reduce endoleak rates by approximately 15% to 20% and improve 24-month patency above 85%. Polymer-coated graft systems are used in about 55% of aneurysm repairs, while heparin-coated variants account for nearly 28%. Device diameters range from 16 mm to 36 mm in 70% of procedures, and delivery system sizes have been reduced by 18% over the past 5 years to enable minimally invasive access.

Peripheral Vascular: Peripheral vascular coated grafts are widely used in treating peripheral artery disease, which affects over 200 million people globally. This segment accounts for approximately 18% of total coated stent graft procedures. Around 58% of femoropopliteal artery interventions involve coated graft placement, reducing restenosis rates from nearly 30% to below 18% within 12 months. Coated devices demonstrate secondary patency rates exceeding 80% at 2 years in 60% of treated patients. Approximately 40% of peripheral interventions are performed in patients aged 65 years and older, and over 50% of these procedures are conducted in hospital-based catheterization laboratories equipped with advanced imaging systems.

Other: The “Other” category represents nearly 7% of coated stent graft applications and includes trauma-related vascular repairs, congenital vascular abnormalities, and complex revascularization cases. Trauma accounts for approximately 12% of emergency vascular interventions globally, with coated grafts used in nearly 35% of these cases to reduce infection and thrombosis risks. In rare vascular malformations, coated graft adoption increased by about 15% between 2021 and 2024. Approximately 20% of complex hybrid surgeries involve customized coated graft solutions. Pediatric vascular repair procedures represent less than 3% of total graft usage but require specialized diameters under 6 mm in nearly 70% of cases.

By Application

Cardiovascular Diseases: Cardiovascular diseases account for nearly 32% of total global deaths, representing approximately 20 million fatalities annually, which drives nearly 46% of total coated stent graft utilization by application. More than 200 million people live with peripheral artery disease, and around 10 million new coronary and vascular intervention procedures are performed each year worldwide. Approximately 60% of complex vascular interventions involve coated stent graft technologies to reduce thrombosis rates by nearly 40% compared to non-coated devices. In patients aged 60 years and above, who represent over 55% of cardiovascular cases, coated graft implantation improves 24-month patency rates above 85% in nearly 65% of treated cases.

Cardiac Aneurysm: Cardiac aneurysm applications represent approximately 28% of the coated stent graft market by application share. Abdominal aortic aneurysm prevalence ranges between 4% and 8% in men over the age of 65, and nearly 200,000 aneurysm repair procedures are conducted annually in developed healthcare systems. Over 65% of these repairs are performed using endovascular techniques, with coated stent grafts used in nearly 75% of cases to reduce endoleak incidence, which occurs in about 15% to 20% of standard procedures. Five-year survival rates improve by nearly 20% when minimally invasive graft placement is performed in high-risk patients representing approximately 30% of total aneurysm diagnoses.

Kidney Failure: Kidney failure accounts for around 19% of total coated stent graft applications, driven by more than 3.5 million dialysis patients worldwide. Approximately 45% of hemodialysis patients require vascular graft access, and coated graft systems are used in nearly 30% of these procedures to reduce infection rates by approximately 25%. In the United States alone, more than 500,000 patients undergo dialysis annually, and nearly 48% rely on synthetic access grafts. Primary patency rates at 12 months exceed 60% in coated dialysis grafts, compared to approximately 45% in non-coated variants. Patients aged above 65 years account for nearly 50% of dialysis-related vascular access procedures.

Other: The “Other” application segment represents roughly 7% of total coated stent graft usage and includes trauma-related vascular injuries, congenital vascular defects, and complex hybrid revascularization procedures. Trauma contributes to nearly 12% of emergency vascular surgeries globally, and coated grafts are utilized in approximately 35% of these interventions to reduce infection and thrombotic complications. Congenital vascular abnormalities account for about 5% of specialized graft procedures, with device diameters under 8 mm used in nearly 60% of such cases. Hybrid procedures combining open and endovascular methods increased by nearly 28% between 2019 and 2024, with coated grafts integrated in approximately 40% of these complex surgical treatments.

Regional Outlook for Coated Stent Graft Market

The Coated Stent Graft Market Outlook demonstrates region-specific procedural volumes, disease prevalence rates, infrastructure capacity, and coated device penetration levels across 4 major regions and more than 25 countries. North America accounts for approximately 38% of global coated stent graft procedure volume, followed by Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa at 7%, while Latin America contributes nearly 4%. Globally, more than 70% of coated stent graft procedures are performed in developed healthcare systems with advanced interventional radiology infrastructure. Over 65% of hospitals performing vascular interventions are located in North America and Europe, whereas Asia-Pacific contributes nearly 46% of global patient volume for peripheral artery disease, influencing long-term Coated Stent Graft Market Share distribution.

North America

North America represents approximately 38% of the global Coated Stent Graft Market Size, driven by high cardiovascular disease prevalence and advanced procedural adoption. More than 20 million adults in the United States suffer from peripheral artery disease, and over 200,000 abdominal aortic aneurysm repairs are performed annually across the region. Approximately 65% of aneurysm repairs are conducted using endovascular techniques, with coated stent grafts utilized in nearly 75% of these procedures. The U.S. has over 6,000 hospitals equipped with interventional cardiology or vascular surgery departments, and nearly 80% of tertiary care centers operate hybrid operating rooms. Dialysis prevalence exceeds 500,000 patients annually in the U.S., with about 45% requiring vascular graft access. Canada reports coated graft utilization rates above 60% in aneurysm repair procedures, while 70% of vascular specialists in the region prefer minimally invasive coated graft solutions due to 25% shorter hospital stays and 30% lower complication rates compared to open surgery.

Europe

Europe accounts for approximately 27% of the global Coated Stent Graft Market Share, supported by aging demographics and structured reimbursement frameworks in more than 20 countries. Abdominal aortic aneurysm prevalence ranges from 4% to 8% in men above 65 years, and nearly 150,000 aneurysm repair procedures are conducted annually across the region. Endovascular repair adoption exceeds 60% in Germany, France, Italy, and the United Kingdom, which collectively represent more than 65% of regional procedure volume. Approximately 40% of vascular graft procedures involve heparin-coated devices to reduce thrombosis rates by nearly 35%. More than 55% of patients undergoing vascular interventions in Europe are aged 60 years or older. Around 75% of tertiary hospitals in Western Europe are equipped with advanced catheterization laboratories, and over 50% of complex vascular interventions are performed using minimally invasive approaches. Eastern Europe shows a 20% increase in endovascular procedure volumes between 2020 and 2024.

Asia-Pacific

Asia-Pacific holds approximately 24% of the global Coated Stent Graft Market Outlook and represents the largest patient base, with more than 46% of the world’s population residing in the region. China accounts for nearly 35% of regional vascular procedure volumes, and Japan records over 90% hospital access to endovascular treatment facilities. Peripheral artery disease affects more than 80 million individuals across Asia-Pacific, contributing to nearly 30% of global case burden. Endovascular aneurysm repair adoption rates exceed 55% in developed markets such as Japan and South Korea. India reports a 25% increase in vascular intervention volumes between 2019 and 2024. Approximately 60% of tertiary hospitals in urban Asia-Pacific are equipped with digital imaging systems for minimally invasive procedures. The population aged 60 years and above represents nearly 30% of the demographic in Japan and 18% in China, driving long-term Coated Stent Graft Market Growth across the region.

Middle East & Africa

The Middle East & Africa region represents approximately 7% of the global Coated Stent Graft Market Share, with significant concentration in Gulf Cooperation Council countries. Cardiovascular diseases account for nearly 40% of total deaths in several Middle Eastern nations, supporting procedural demand. Endovascular adoption rates exceed 70% in tertiary hospitals across the United Arab Emirates and Saudi Arabia. South Africa performs more than 15,000 vascular interventions annually, with coated graft usage reaching nearly 45% in complex aneurysm cases. Dialysis patient populations in the region increased by approximately 20% between 2019 and 2024, influencing hemodialysis access graft demand. Around 35% of advanced vascular procedures are conducted in private hospitals equipped with hybrid operating rooms. Infrastructure expansion projects increased catheterization laboratory capacity by nearly 18% in major urban centers across the region between 2020 and 2024.

List of Top Coated Stent Graft Companies

• Abbott Laboratories
• Cordis Corporation
• Boston Scientific
• BD
• Medtronic
• Jotec
• Lifetech Scientific
• BIOTRONIK
• Gore Medical
• Merit Medical
• MicroPort

Top 2 Companies by Market Share:

• Medtronic – approximately 24% global share in endovascular stent graft segment.
• Gore Medical – nearly 20% share in coated vascular graft supply worldwide.

Investment Analysis and Opportunities

Approximately 45% of medical device R&D budgets in vascular segments focus on coated graft technologies. Over 30 clinical trials were initiated between 2022 and 2024 for next-generation polymer coatings. Around 42% of investments target drug-eluting graft platforms. Emerging markets show 35% growth in vascular procedure volumes, increasing infrastructure expansion by 28%. Nearly 50% of private equity funding in cardiovascular devices supports minimally invasive technologies.

Hospital capital expansion captured 18%–28% of investments in imaging and hybrid OR capacity, supporting adoption of coated grafts in >6,000 tertiary hospitals across developed markets. Private equity activity included at least one notable PE investment into a vascular technology firm in 2025, reinforcing exit interest in the space. These allocation figures translate into direct support for clinical programs: there are dozens of device-specific clinical trials and registries recruiting or active for covered/coated stent-graft platforms in 2023–2025, which underpin near-term product commercialization and procurement pipelines.

New Product Development

Product innovation accelerated from 2023 through 2025 with regulators and developers clearing and piloting lower-profile and bioactive-coated platforms: for example, a low-profile heparin-bonded balloon-expandable covered stent received US FDA approval (Viabahn VBX) on 1 Feb 2024, and other manufacturers secured CE marks or national approvals (one notable CE mark was granted for a balloon-expandable covered stent in 2022). Pipeline intelligence identifies 73 aortic stent-graft devices in various stages of development globally, spanning fenestrated, branched, thoracic and peripheral applications.

Device advances reduced delivery-system diameters by roughly 15%–20% in recent product generations, enabling access to vessels under 5 mm in selected cases; manufacturers reported durability targets beyond 10 years for premium polymer coatings and clinical studies showing primary patency improvements of >15–25 percentage points at 12–24 months for heparin-bonded systems. R&D activity also increased the number of investigator-initiated registries and randomized trials, with multiple IDE and multicenter studies enrolling 100–500+ patients each to validate next-gen coated and drug-eluting graft variants.

Five Recent Developments

• Medtronic launched next-gen coated graft with 15% improved flexibility.
• Gore Medical introduced heparin-bonded graft reducing thrombosis by 38%.
• Boston Scientific expanded coated graft portfolio across 12 countries.
• Abbott initiated clinical trial with 500+ patient enrollment.
• MicroPort achieved 90% procedural success rate in coated graft study.

Report Coverage of Coated Stent Graft Market

Market intelligence and pipeline reports covering coated stent grafts commonly span 4–6 regions and 20+ countries, evaluate 50+ manufacturers and track 70+ to 100+ product variants and pipeline entries introduced between 2019 and 2025. Example coverage models list segmentation across 15+ device categories (aortic, thoracic, fenestrated, iliac, peripheral, hemodialysis access), 6+ coating technologies (heparin-bonded, polymeric, drug-eluting, bioactive, PTFE/ePTFE liners), and 4 primary applications (AAA/TAA, peripheral vascular, dialysis access, trauma/congenital), plus regulatory and reimbursement mapping across 12 major compliance frameworks.

Reports also integrate clinical evidence by citing dozens of active ClinicalTrials.gov records and registry datasets and by synthesizing 200+ expert interviews and 300+ quantitative datapoints (procedure volumes, device penetration rates, hospital capacity counts). Typical competitive benchmarking ranks the top 10 suppliers that together account for a large share of unit shipments and supply contracts, while pipeline reports enumerate 20+ firms with active development programs in thoracic and aortic covered stent categories.